🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%

EntrackrEntrackr · 1m ago
Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%
Medial

MediBuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37% Following more than 2X growth in the fiscal year ending March 2024, digital healthcare platform MediBuddy reported modest growth in its operating scale in FY25, while managing to narrow its losses by 37% during the period. MediBuddy's operating revenue grew 12.3% year-on-year to Rs 724.6 crore in FY25 from Rs 645.4 crore in the previous fiscal year (FY24), according to the company's annual financial statements filed with the Registrar of Companies (RoC). MediBuddy, a digital healthcare platform, provides online and offline medical consultations, medicine delivery, lab tests, surgeries, and insurance services, with revenue from these forming the primary source of income at Rs 722 crore, supplemented by Rs 2.5 crore from other operating sources. The company also earned Rs 18.42 crore from non-operating sources, including interest on fixed deposits and current investments, written-off liabilities, and other miscellaneous income, pushing its total income to Rs 743 crore in FY25. On expenses, the cost of materials was the largest at 38% of total expenses, standing at Rs 333 crore. Employee benefits expenses rose marginally by 8% to Rs 176.8 crore, including Rs 6 crore in ESOP expenses. Sales payout expenses, including commissions to selling agents, fell 7% to Rs 155.47 crore. The company spent Rs 42.5 crore on safety and security and Rs 32.5 crore on IT. Other overheads, including legal and professional fees, advertising, depreciation and amortization, and finance costs, amounted to Rs 138.7 crore. Overall expenses for the Bengaluru-based firm remained flat at Rs 879 crore, with controlled expenditure and a 12% rise in revenue helping to narrow losses by 37% to Rs 137 crore from Rs 215.7 crore in FY24. On a unit basis, MediBuddy spent Rs 1.21 to earn one rupee of operating revenue, with its EBITDA margin improving to -14.19% in FY25 from -25.67% in the previous year, resulting in an EBITDA loss of Rs 103 crore. As of March 2024, MediBuddy's current assets were Rs 395.2 crore, including cash and bank balances of Rs 80 crore. MediBuddy has raised over $190 million to date, last raising $18 million in August 2023 from existing investors Quadria Capital, Lightrock, and TEAMFund. It competes with companies including Pristyn Care-owned Lybrate, Practo, and mFine Tata 1mg.

Smytten cuts losses by 41% in FY25; revenue slips to Rs 111 Cr

EntrackrEntrackr · 4m ago
Smytten cuts losses by 41% in FY25; revenue slips to Rs 111 Cr
Medial

Smytten cuts losses by 41% in FY25; revenue slips to Rs 111 Cr Smytten, a product discovery and trial platform, improved its expense discipline and significantly narrowed losses, but the revenue decline highlights its continuing struggle to achieve sustainable growth in FY25. The company’s revenue from operations declined 10.5% to Rs 111 crore in FY25 from Rs 124 crore in FY24, according to its provisional financial statement sourced from the Registrar of Companies (RoC). Smytten derives its income largely from product trials and allied services for D2C and FMCG brands. The firm also generates ancillary revenues through brand promotions and partnerships. The company did not provide a revenue breakup in its provisional financial statements. On the expense front, the cost of materials, the firm’s largest expense, declined 17% to Rs 58 crore in FY25 from Rs 70 crore in FY24. Employee benefit expenses fell 9% to Rs 20 crore, while details of other overheads, including marketing, tech, and operational costs, were not disclosed. Overall, the company managed to reduce its total expenses by 21% to Rs 131 crore in FY25 from Rs 165 crore in FY24. The sharper control on expenses helped Smytten cut its losses by 41% to Rs 23.5 crore, as compared to Rs 40 crore in FY24. Its ROCE and EBITDA margin stood at -76.92% and -16.92%, respectively. On a per-unit basis, the firm spent Rs 1.18 to earn a rupee of revenue in the last fiscal year. As of March 2025, the Bengaluru-based company reported current assets worth Rs 67 crore, including Rs 20 crore in cash and bank balances. According to TheKredible, Smytten has raised a total of $22 million of funding till date, having Roots Ventures and Fireside Ventures as its lead investors. The company’s co-founders Siddhartha Nangia and Swagata Sarangi together own 39.32% of the company.

Download the medial app to read full posts, comements and news.